HK1144306A1 - 激酶抑制劑及其用途 - Google Patents
激酶抑制劑及其用途Info
- Publication number
- HK1144306A1 HK1144306A1 HK10110773.0A HK10110773A HK1144306A1 HK 1144306 A1 HK1144306 A1 HK 1144306A1 HK 10110773 A HK10110773 A HK 10110773A HK 1144306 A1 HK1144306 A1 HK 1144306A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- kinase inhibitors
- kinase
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96394107P | 2007-08-07 | 2007-08-07 | |
US99497007P | 2007-09-24 | 2007-09-24 | |
PCT/US2008/072525 WO2009021137A2 (en) | 2007-08-07 | 2008-08-07 | Kinase inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1144306A1 true HK1144306A1 (zh) | 2011-02-11 |
Family
ID=40342047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10110773.0A HK1144306A1 (zh) | 2007-08-07 | 2010-11-18 | 激酶抑制劑及其用途 |
Country Status (7)
Country | Link |
---|---|
US (2) | US8741849B2 (zh) |
EP (1) | EP2185698B1 (zh) |
JP (1) | JP5703466B2 (zh) |
DK (1) | DK2185698T3 (zh) |
ES (1) | ES2547229T3 (zh) |
HK (1) | HK1144306A1 (zh) |
WO (1) | WO2009021137A2 (zh) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080293640A1 (en) * | 2007-01-10 | 2008-11-27 | Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of | Polypeptide inhibitors of HSP27 kinase and uses therefor |
EP2617431B1 (en) * | 2007-01-10 | 2017-04-12 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therefor |
DK2185698T3 (en) | 2007-08-07 | 2015-07-27 | Purdue Research Foundation | Kinase Inhibitors and Uses thereof |
BRPI0919759A2 (pt) * | 2008-10-20 | 2017-03-21 | Moerae Matrix Inc | polipeptídeos para tratamento e prevenção de adesões |
WO2010068692A1 (en) * | 2008-12-10 | 2010-06-17 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
AU2013202108B2 (en) * | 2008-12-10 | 2015-12-24 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
US9890195B2 (en) | 2009-07-27 | 2018-02-13 | Purdue Research Foundation | MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
US8530429B2 (en) * | 2009-11-24 | 2013-09-10 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
US9095541B2 (en) | 2009-11-24 | 2015-08-04 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
MY191934A (en) | 2010-05-20 | 2022-07-19 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors |
US20130115256A1 (en) * | 2010-05-24 | 2013-05-09 | Cynthia Lander | Methods for treating or preventing vascular graft failure |
CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
EP3763740A1 (en) | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
BR112013026313A8 (pt) | 2011-04-12 | 2018-01-30 | Moerae Matrix Inc | composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular |
CN102949722A (zh) * | 2011-08-26 | 2013-03-06 | 中国医学科学院放射医学研究所 | 基于p38抑制剂和细胞生长因子的新颖药物组合物 |
WO2013063458A2 (en) | 2011-10-27 | 2013-05-02 | Mayo Foundation For Medical Education And Research | Inhibiting g protein coupled receptor 6 kinase polypeptides |
US10202643B2 (en) | 2011-10-31 | 2019-02-12 | University Of Utah Research Foundation | Genetic alterations in glioma |
WO2013134636A1 (en) | 2012-03-09 | 2013-09-12 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
AU2013234955A1 (en) | 2012-03-23 | 2014-11-13 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
MX2015001081A (es) | 2012-07-24 | 2015-10-14 | Pharmacyclics Inc | Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk). |
CN110256559B (zh) | 2012-07-25 | 2023-05-26 | 塞尔德克斯医疗公司 | 抗kit抗体及其用途 |
US20140072613A1 (en) * | 2012-09-10 | 2014-03-13 | Cynthia Lander | Compositions and Methods for Treating Cutaneous Scarring |
WO2014160364A1 (en) * | 2013-03-13 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer |
KR20150143639A (ko) | 2013-04-11 | 2015-12-23 | 벤더르빌트 유니버시티 | 폴리플렉스 |
GB201314610D0 (en) | 2013-08-15 | 2013-10-02 | Blueberry Therapeutics Ltd | Compounds and their uses |
US9644037B2 (en) | 2013-10-18 | 2017-05-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use |
CN103739678B (zh) * | 2013-12-31 | 2015-09-02 | 刘培臣 | 抑制粘附斑激酶多肽及其应用 |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
US9902739B2 (en) | 2014-04-21 | 2018-02-27 | Mayo Foundation For Medical Education And Research | Small molecule inhibitors of G protein coupled receptor 6 kinases polypeptides |
CN113908269A (zh) | 2014-05-23 | 2022-01-11 | 塞尔德克斯医疗公司 | 嗜酸性粒细胞或肥大细胞相关病症的治疗 |
BR112017002232A2 (pt) * | 2014-08-08 | 2018-07-24 | Janssen Pharmaceutica Nv | combinações de inibidor de tirosina quinase de bruton e usos das mesmas |
WO2016032882A1 (en) * | 2014-08-25 | 2016-03-03 | Stc.Unm | Inhibition of mk2 in the treatment of cancer |
BR112017010238A2 (pt) | 2014-11-17 | 2018-02-06 | Moerae Matrix, Inc. | composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação de fibroblastos e a deposição aberrante de matriz extracelular |
JP2018502860A (ja) | 2015-01-08 | 2018-02-01 | モイライ マトリックス インコーポレイテッド | Mk2阻害ペプチド製剤 |
MX2017011633A (es) * | 2015-03-12 | 2017-11-02 | Moerae Matrix Inc | Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas. |
DK3322706T3 (da) | 2015-07-16 | 2021-02-01 | Array Biopharma Inc | Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer |
US11091472B2 (en) | 2016-02-26 | 2021-08-17 | The Regents Of The University Of California | PI-kinase inhibitors with anti-infective activity |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
JP7061195B2 (ja) | 2018-01-18 | 2022-04-27 | アレイ バイオファーマ インコーポレイテッド | RETキナーゼ阻害剤としての置換ピラゾロ[3,4-d]ピリミジン化合物 |
JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピロロ[2,3-d]ピリミジン化合物 |
WO2019218016A1 (en) | 2018-05-15 | 2019-11-21 | Interk Peptide Therapeutics Limited | Peptide activating agent |
EP3794015A4 (en) * | 2018-05-15 | 2022-03-30 | InterK Peptide Therapeutics Limited | ACTIVATING AGENTS |
ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
CA3126143A1 (en) * | 2019-01-11 | 2020-07-16 | The Board Of Trustees Of The Leland Stanford Junior University | Pi4-kinase inhibitors with anti-cancer activity |
WO2021097407A2 (en) * | 2019-11-15 | 2021-05-20 | Regents Of The University Of Colorado, A Body Corporate | Novel peptide compositions and methods of treating neurological injury |
CN114605497B (zh) * | 2021-02-10 | 2023-04-28 | 北京欣安诚科技有限公司 | 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途 |
CN115976033A (zh) * | 2022-12-14 | 2023-04-18 | 西南大学 | 瓜实蝇tssk1和tssk3基因及其应用 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1521000A (en) * | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
US4192309A (en) * | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
US4227522A (en) * | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
LU85034A1 (fr) * | 1982-10-08 | 1985-06-19 | Glaxo Group Ltd | Dispositifs en vue d'administrer des medicaments a des patients |
US4778054A (en) * | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
GB2178965B (en) * | 1985-07-30 | 1988-08-03 | Glaxo Group Ltd | Devices for administering medicaments to patients |
US5175144A (en) * | 1988-11-29 | 1992-12-29 | The Johns Hopkins University | Method of retarding the progression of chronic renal failure |
JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
CA2080224A1 (en) * | 1990-04-18 | 1991-10-19 | Jindrich Kopecek | Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting ph-dependent swelling |
AU4115693A (en) | 1992-04-24 | 1993-11-29 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
WO1995015972A1 (en) * | 1993-12-09 | 1995-06-15 | Thomas Jefferson University | Compounds and methods for site-directed mutations in eukaryotic cells |
JP2002505077A (ja) * | 1997-12-10 | 2002-02-19 | ワシントン大学 | 抗病原体システムおよびその使用方法 |
US7041814B1 (en) * | 1998-02-18 | 2006-05-09 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics |
CA2293605A1 (en) * | 1998-04-11 | 1999-10-21 | Paolo Luca Maria Giorgetti | Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application |
US7601685B2 (en) * | 1998-08-27 | 2009-10-13 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
US7615373B2 (en) * | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
US20020009491A1 (en) * | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
EP1309360B1 (en) * | 2000-08-15 | 2006-04-19 | SurModics, Inc. | Medicament incorporation matrix |
EP1351702B1 (en) * | 2000-12-08 | 2015-03-04 | Bioprovar Corporation | Trem-1 splice variant for use in modifying immune responses |
CA2434643C (en) * | 2001-01-18 | 2013-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for activation and inhibition of.delta.pkc |
DE10118774A1 (de) | 2001-04-17 | 2002-10-31 | Jerini Ag | Verfahren zur Bestimmung der Substratspezifität einer enzymatischen Aktivität und Vorrichtung hierzu |
US7361352B2 (en) * | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
WO2003018758A2 (en) * | 2001-08-23 | 2003-03-06 | Arizona Board Of Regents | Reagents and methods for smooth muscle therapies |
US20030134810A1 (en) * | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
WO2003072801A2 (en) * | 2002-02-21 | 2003-09-04 | The Rockefeller University | Compositions and method for regulation of calcium-dependent signalling in brain |
US20040005686A1 (en) | 2002-03-07 | 2004-01-08 | Pharmacia Corporation | Crystalline structure of human MAPKAP kinase-2 |
WO2003084481A2 (en) * | 2002-04-01 | 2003-10-16 | Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Biological affinity based delivery systems |
US7364870B2 (en) | 2002-08-02 | 2008-04-29 | Wyeth | MK2 interacting proteins |
BR0317525A (pt) | 2002-12-20 | 2005-11-16 | Pharmacia Corp | Compostos pirazol acìclico, composição terapêutica e farmacêutica, kit, bem como respectivos usos |
ES2338350T3 (es) | 2003-02-21 | 2010-05-06 | Arizona Board Of Regents | Utilizacion de hsp20 para estimular la cicatrizacion de heridas y/o para reducir la formacion de cicatrices. |
IL156429A0 (en) | 2003-06-12 | 2004-01-04 | Peptor Ltd | Cell permeable conjugates of peptides for inhibition of protein kinases |
JP2007508823A (ja) | 2003-10-17 | 2007-04-12 | アリゾナ ボード オブ リージェンツ | 新規な熱ショックタンパク質20関連ポリペプチドおよびその使用 |
WO2005114221A2 (en) | 2004-05-21 | 2005-12-01 | The Institute For Systems Biology | Compositions and methods for quantification of serum glycoproteins |
AU2005332637B2 (en) * | 2004-07-23 | 2011-04-07 | The Trustees Of The University Of Pennsylvania | Antimicrobial copolymers and uses thereof |
AU2005304638A1 (en) * | 2004-11-12 | 2006-05-18 | Massachusetts Institute Of Technology | Methods and compositions for treating cellular proliferative diseases |
WO2006071456A2 (en) | 2004-12-02 | 2006-07-06 | The University Of North Carolina At Chapel Hill | Inhibition of hsp27 phosphorylation for treatment of blistering disorders |
WO2006105278A2 (en) * | 2005-03-29 | 2006-10-05 | The Regents Of The University Of California | Controlling stem cell destiny destiny with tunable network |
US7767642B2 (en) * | 2005-04-15 | 2010-08-03 | Arizona Biomedical Research Commission | Therapeutic peptides for the treatment of metastatic cancer |
EP1948259B1 (en) * | 2005-10-26 | 2017-03-22 | Genesis Technologies Limited | Acellular bioabsorbable tissue regeneration matrices produced by incubating acellular blood products |
CN101426808A (zh) | 2005-11-01 | 2009-05-06 | 亚利桑那董事会,代表亚利桑那州立大学行事的法人团体 | 新颖的蛋白质转导结构域及其应用 |
US20070154448A1 (en) * | 2005-11-22 | 2007-07-05 | Ted Reid | Methods and compositions using Substance P to promote wound healing |
KR101267217B1 (ko) | 2006-07-12 | 2013-05-31 | 아리조나 보드 오브 리젠츠 퍼 앤 온 비하프 오브 아리조나 스테이트 유니버시티 | 섬유증 장애 및 켈로이드의 치료 및 억제 방법 |
EP2617431B1 (en) | 2007-01-10 | 2017-04-12 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therefor |
US20080293640A1 (en) * | 2007-01-10 | 2008-11-27 | Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of | Polypeptide inhibitors of HSP27 kinase and uses therefor |
DK2185698T3 (en) | 2007-08-07 | 2015-07-27 | Purdue Research Foundation | Kinase Inhibitors and Uses thereof |
US20090269406A1 (en) * | 2008-04-02 | 2009-10-29 | Alyssa Panitch | Therapeutic uses of biocompatible biogel compositions |
BRPI0919759A2 (pt) | 2008-10-20 | 2017-03-21 | Moerae Matrix Inc | polipeptídeos para tratamento e prevenção de adesões |
WO2010068692A1 (en) | 2008-12-10 | 2010-06-17 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
US9890195B2 (en) * | 2009-07-27 | 2018-02-13 | Purdue Research Foundation | MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
US20130115256A1 (en) * | 2010-05-24 | 2013-05-09 | Cynthia Lander | Methods for treating or preventing vascular graft failure |
BR112013026313A8 (pt) | 2011-04-12 | 2018-01-30 | Moerae Matrix Inc | composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular |
-
2008
- 2008-08-07 DK DK08797416.8T patent/DK2185698T3/en active
- 2008-08-07 US US12/188,109 patent/US8741849B2/en not_active Expired - Fee Related
- 2008-08-07 WO PCT/US2008/072525 patent/WO2009021137A2/en active Application Filing
- 2008-08-07 ES ES08797416.8T patent/ES2547229T3/es active Active
- 2008-08-07 EP EP20080797416 patent/EP2185698B1/en not_active Not-in-force
- 2008-08-07 JP JP2010520314A patent/JP5703466B2/ja not_active Expired - Fee Related
-
2010
- 2010-11-18 HK HK10110773.0A patent/HK1144306A1/zh not_active IP Right Cessation
-
2014
- 2014-04-22 US US14/258,418 patent/US9447158B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP5703466B2 (ja) | 2015-04-22 |
US20140342993A1 (en) | 2014-11-20 |
WO2009021137A3 (en) | 2009-07-09 |
US20090149389A1 (en) | 2009-06-11 |
EP2185698A2 (en) | 2010-05-19 |
DK2185698T3 (en) | 2015-07-27 |
JP2010535508A (ja) | 2010-11-25 |
EP2185698B1 (en) | 2015-04-22 |
EP2185698A4 (en) | 2012-03-28 |
US9447158B2 (en) | 2016-09-20 |
ES2547229T3 (es) | 2015-10-02 |
WO2009021137A2 (en) | 2009-02-12 |
US20130184221A9 (en) | 2013-07-18 |
US8741849B2 (en) | 2014-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2200052I1 (hu) | Imidazotriazinok és imidazopirimidinek mint kinázgátlók | |
HK1144306A1 (zh) | 激酶抑制劑及其用途 | |
ZA201004055B (en) | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors | |
IL211549A0 (en) | Aminotriazolopyridines and their use as kinase inhibitors | |
EP2200977A4 (en) | F1F0-ATPASE INHIBITOR AND ASSOCIATED METHODS | |
HK1140767A1 (zh) | 激酶抑制劑 | |
ZA200901073B (en) | Kinase inhibitor | |
IL212755A0 (en) | Pyrazinopyrazines and derivatives as kinase inhibitors | |
IL207415A0 (en) | Protein kinase inhibitors and use thereof | |
ZA201003420B (en) | Protein kinase inhibitors and use thereof | |
HK1137756A1 (zh) | 取代二氫吡唑啉酮和它們作爲 -脯氨酰- -羥化酶抑制劑的用途 | |
EP2379076A4 (en) | PHOSPHODIESTERASE HEMMER AND ITS USES | |
ZA200908943B (en) | Pyrazolopyrimidinone kinase inhibitor | |
IL197981A0 (en) | Kinase inhibitors | |
GB0715470D0 (en) | IKK- serine-threonine protein kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AM | Amended specification (according sect 146 of patent law) |
Free format text: ADDITION OF INVENTOR: WARD, BRIAN Effective date: 20160225 |
|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210807 |